Success Metrics

Active Trials

1(25%)

Phase Distribution

Ph not_applicable

75%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 3Large-scale testing

1(25.0%)

N/ANon-phased studies

3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Other(2)

Detailed Status

unknown2

Not yet recruiting1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Phase 31 (25.0%)

N/A3 (75.0%)

Trials by Status

not_yet_recruiting125%

recruiting125%

unknown250%

Recent Activity

1 active trials

Showing 4 of 4

recruitingnot_applicable

The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer

NCT02920554

unknownnot_applicable

Wedge Resection or Parietal Pleurectomy for the Treatment of Recurrent Pneumothorax (WOPP)

NCT01855464

not_yet_recruitingphase_3

Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)

NCT06102161

unknownnot_applicable

Comparison Between Wedge Resection and Segmentectomy for Ground Glass Opacity- Dominant Stage IA NSCLC

NCT02718365

Clinical Trials (4)

Showing 4 of 4 trials

NCT02920554Not Applicable

The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer

Recruiting

NCT01855464Not Applicable

Wedge Resection or Parietal Pleurectomy for the Treatment of Recurrent Pneumothorax (WOPP)

Unknown

NCT06102161Phase 3

Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)

Not Yet Recruiting

NCT02718365Not Applicable

Comparison Between Wedge Resection and Segmentectomy for Ground Glass Opacity- Dominant Stage IA NSCLC

Unknown

All 4 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 4